Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cystic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2021: Trial registered, NCT04895735
  2. 23 Jul 2021: Trial started, NCT04895735

The trials

NCT04895735: MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

State
Under way
Phase
Phase 2
People
45 taking part
Started
23 Jul 2021
Primary completion
13 Aug 2025
Arms
Treatment (pembrolizumab, pemetrexed)
Results
Posted on the registry
  1. 20 May 2021: Trial registered
  2. 23 Jul 2021: Trial started
  3. 4 Jun 2026: Trial results posted

Posted results

The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.

Confirmed Response Rate

Primary outcome · Number, proportion of participants · 24 weeks

GroupAnalysedValue
Cohort A (Adenoid Cystic Carcinoma)110 (95% Confidence Interval 0 to 0.28)
Cohort A1 (ACC Patients Enrolled Starting With MCCC Amendment 3)90.11 (95% Confidence Interval 0 to 0.48)
Cohort B (Non-adenoid Cystic Carcinoma)240.375 (95% Confidence Interval 0.19 to 0.59)

Clinical Benefit Rate (CBR)

Primary outcome · Number, proportion of patients · 24 weeks

GroupAnalysedValue
Cohort A110.727 (95% Confidence Interval 0.390 to 0.940)
Cohort A191.0 (95% Confidence Interval 0.664 to 1.0)
Cohort B (Non-adenoid Cystic Carcinoma)240.583 (95% Confidence Interval 0.366 to 0.779)

Incidence of Adverse Events

Secondary outcome · Number of participants · 27 months

GroupAnalysedValue
Cohort A118
Cohort A198
Cohort B (Non-adenoid Cystic Carcinoma)2419

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.